The interactions between gefitinib and NO discussed above are also relevant in the context of HER2 as the response to gefitinib in breast cancer was found to be independent of EGFR expression but influenced by HER2 overexpression (Campiglio et al., 2004). Here, EGFR is linked to breast carcinoma.